INTRODUCTION
Since the late 1970s, pediatric Hodgkin lymphoma (HL) has been treated succesfully in cooperative group trials.
1-5 Initially, high-dose extended-field radiation proved to be effective in adults with earlystage disease, whereas chemotherapy combinations of mechlorethamine, vincristine, procarbazine, and prednisone as well as doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or combined-modality treatment were reserved for advanced disease. 6 These treatments were modified for children by reducing radiation dose and field size and relying on chemotherapy across all disease stages. With increasing concerns about aging survivors of pediatric cancer, 7-9 general treatment approaches for the disease have changed. The use of alkylators has been reduced and the number and composition of chemotherapy cycles have been adapted to individual risk factors.
2-4,10,11
Radiotherapy (RT) has been limited to involved fields and doses adapted to disease risk.
1,4 The concept of using early response to tailor therapy in dose-dense regimens has been refined. 11 Procarbazine has been gradually eliminated to reduce the risk of infertility, and etoposide and doxorubicin substituted to reduce the cumulative alkylating agent dose.
11-14
For more than 30 years, collaborations among cooperative groups globally have led to varied treatment approaches for pediatric HL. North American and most European study groups 4,13,15-24 have favored combined-modality treatment approaches, whereas Central and South American groups [25] [26] [27] have initially pursued chemotherapy-only regimens (Table 1) . Since 2005, most European groups have been working together under the umbrella of the European Network for Pediatric Hodgkin Lymphoma (EuroNet-PHL). The Pediatric Oncology Group and Children's Cancer Group have merged to form the Children's Oncology Group (COG), and the Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA) and the Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) have also recently agreed to implement the same protocol with the prospect of more South American sites to follow.
There is an increasing need to harmonize the staging and response criteria (eg, [ Table A1) . 40 In this trial, all patients receive OEPA, but patients in the intermediate-and high-risk groups-treatment groups 2 and 3-are randomly assigned to receive COPP or COPDAC to test whether equivalent results can be achieved with a less gonadotoxic procarbazine-free regimen.
Similarly, the Pediatric Oncology Group developed a dose-dense procarbazine-free regimen comprising doxorubicin, bleomycin, vincristine, and etoposide and prednisone and cyclophosphamide. 11 In the original P9425 and P9426 trials, patients were randomly assigned to receive the topoisomerase inhibitor dexrazoxane as a cardiopulmonary protectant during treatment. 50 Early evaluation of dexrazoxaneassociated second malignant neoplasms suggested an increased risk for secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome, with 6 of 8 patients in the dexrazoxane arm developing AML/myelodysplastic syndrome and 2 patients developing solid tumors. The 4-year cumulative incidence rate of any secondary malignancy was 2.55% for patients in the dexrazoxane arm versus 0.85% for those in the nondexrazoxane arm (P ϭ .06). Subsequent COG trials have therefore discouraged the use of dexrazoxane, and the risk of sAML in the nondexrazoxane arm seems to be low. In the GPOH-HD-2002 trial, none of the 287 boys receiving the etoposidecontaining regimen developed sAML, whereas 1 girl who did not receive etoposide developed sAML. 13 The Stanford V regimen adopted by the St Jude-Stanford-Dana Farber consortium is a combined-modality strategy originally developed by an adult study group 51 in which a 12-week, multiagent, non-cross-resistant dosedense regimen combined with involved-field RT (IFRT) was given to patients with intermediate-and advanced-stage HL (Appendix Table  A1 ).
52 Mature long-term data from Stanford V show a low risk of sAML for patients administered this regimen, with none of the 256 patients observed for more than 5 years developing sAML. 53 In this regimen, low cumulative doses of alkylating agents also improve the prospects of fertility.
Response Adaptation to Reduce or Eliminate RT
In HL trials on adults, RT remains an essential component of treatment, especially for patients with early-stage disease who are treated with ABVD chemotherapy. In contrast, pediatric HL study groups balance the risk-benefit ratio differently. Although combined-modality approaches usually provide high response rates with event-free survival (EFS) rates of approximately 90%, the risk of radiation-induced second cancers, cardiovascular disease, and thyroid dysfunction in survivors of pediatric HL increases throughout their lifetime. The CCG trial C5942, one of the first pediatric trials aimed at eliminating RT, randomly assigned patients who had achieved anatomic complete response (CR) after completion of COPP/ABV hybrid chemotherapy to either IFRT or no further therapy. 36 The 10-year EFS rate, but not the overall survival (OS) rate, was significantly lower among those treated with chemotherapy alone. 56 However, this trial was compromised by the use of less intensive chemotherapy than is used in most contemporary trials. Despite international collaborations, randomized clinical trials to evaluate the added benefit of RT remain challenging in pediatric HL because the limited number of patients makes it difficult to achieve statistical power. Therefore, most collaborative consortia are adopting a response-based RT delivery in which patients with an early favorable response to chemotherapy are chosen to undergo reduced RT or forgo it completely. The St JudeStanford-Dana Farber consortium evaluated response-based radiation in low-risk patients treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) chemotherapy. RT was administered only to patients who did not achieve an early, that is, after two cycles of VAMP, anatomic and metabolic CR. The 5-year EFS rates of patients treated with four cycles of VAMP chemotherapy alone and four cycles of VAMP chemotherapy plus 25.5 Gy IFRT 28 were similar (Table 2 ).
In the GPOH-HD95 trial, RT was omitted in patients achieving anatomic CR after OEPA-COPP chemotherapy. The 10-year progression-free survival (PFS) rate for patients with intermediateand advanced-stage disease (69% and 83%, respectively) was significantly lower for patients with a CR than for those who did not achieve a CR and received IFRT. The PFS rates for patients with low-risk disease that did and did not receive RT were similar. 18 However, the OS rates of patients in all treatment groups were excellent and similar. Thus, assessment by anatomic response at completion of chemotherapy might not be adequate to identify patients who can receive reduced RT without increasing the risk of relapse.
Among more contemporary pediatric trials, moderately doseintensified chemotherapy regimens have facilitated RT reduction strategies. Early response assessment after more intensive doxorubicin, bleomycin, vincristine, and etoposide and prednisone and cyclophosphamide chemotherapy in the COG AHOD0031 trial identified a group of early responders for whom RT could be eliminated without compromising long-term survival. 38 This study enrolled 1,712 eligible patients and is the only random assignment phase III trial to assess treatment stratification on the basis of early response. The EFS rate of rapid early responders with an anatomic response of more than 80% after two cycles and a negative gallium 67 or FDG-PET scan at the end of all chemotherapy did not improve with the addition of RT. Similarly, preliminary results of the COG AHOD0431 trial for low-risk HL seem to have identified a group of very early responders (negative PET scan after one cycle) who may have an improved outcome without adjuvant RT. 57 It is therefore not surprising that response assessment has evolved, and, currently, more value is placed on functional assessment by PET scans.
Recently, EuroNet-PHL completed its first large cooperative trial (EuroNet-PHL-C1) on the basis of the GPOH-HD chemotherapy backbone (OEPA-COPP/COPDAC) in which more than 2,100 patients were recruited. IFRT was administered only to patients whose PET scans were positive after two initial OEPA cycles. Preliminary results suggest that this strategy is feasible to identify patients who can have good long-term survival without RT. Table 3 summarizes the most recent strategies used to reduce or eliminate RT in pediatric and adult HL trials. Although in seminal pediatric trials early response adaptation was a key feature in combined-modality approaches for eliminating RT in all risk groups, elimination of RT is the main objective only in adult patients with advanced-stage HL. RT remains a standard treatment element in adult patients with early-and intermediate-stage disease.
58-60 Essentially, more intensive chemotherapy might be required to balance the elimination of RT. Table 4 presents strategies for the systematic reduction of radiation dose and field size as well as for omitting RT in patients with early-stage classical HL (cHL). The table highlights the development of RT regimens over eight consecutive trials of the DAL/GPOH-HD/EuroNet-PHL groups.
Rationale for Therapy Approach and Response Adaptation in Low-and Middle-Income Countries
In many low-and middle-income countries, health care institutions that lack reliable access to radiation facilities, trained personnel, and diagnostic imaging modalities have traditionally preferred chemotherapy-only approaches. Earlier chemotherapy-only trials prescribed six to 12 cycles of mechlorethamine, vincristine, procarbazine, and prednisone 61, 62 ; hybrid therapies containing alkylating agents, such as chlorambucil, vinblastine, procarbazine, and prednisone 63 ; or alternating non-cross-resistant regimens, such as COPP/ ABVD, 64,65 COPP/ABV hybrids, 66,67 or their combinations without alkylating chemotherapy agents.
68 GATLA evaluated chemotherapy alone versus combined-modality therapy prospectively for early-stage disease (stages I and II). The addition of IFRT improved the diseasefree survival rates for patients with more than two involved nodal areas, bulky peripheral (Ͼ 5 cm) adenopathy, bulky mediastinal adenopathy, or advanced-stage disease. 69 The next GATLA trial found similar EFS rates for patients with favorable prognosis who were randomly assigned to three or six cycles of chemotherapy; the results of the chemotherapy-only approach were not different from the combined-modality strategy of their previous trial.
70
The Central American study group AHOPCA reported a 5-year EFS of 61% with COPP with or without ABV and without RT across all stages. Abandonment of therapy was the major factor affecting the EFS rate, and substantial myelosuppression, especially for high-risk patients, made this regimen difficult to administer (Table 2) . 26 In an effort to reduce abandonment of therapy, AHOPCA switched to a modified Stanford V regimen in 2004. Because preliminary results suggested no improvement in EFS rates, in 2009, AHOPCA moved to OEPA-COPDAC chemotherapy for this patient group (Appendix Table A1 ).
43,71 AHOPCA, GATLA, and other South American institutions are now sharing the same protocol, which uses ABVD for low-and intermediate-risk patients and OEPA-COPDAC for advanced-stage HL. A response-adapted approach is used to prescribe RT. Given that the protocol is shared in Central and South America, but PET-CT (computed tomography) is only available in some of the South American sites, we will be able to compare the impact of an anatomic response assessment versus a combined anatomic and functional response assessment on the number of patients ultimately receiving RT and the EFS rates of the respective approaches. Because prevention of abandonment and treatment-related deaths are other major challenges in low-and middle-income countries, the CAYAHL platform facilitates problem solving and improving the survival of patients.
STANDARDIZING THE DEFINITIONS FOR FDG-PET EVALUATION
FDG-PET images are currently interpreted visually, which is subject to high interobserver variability, 72 and should therefore be centrally reviewed within a clinical trial for quality assurance. The five-point Deauville score, currently the widely used evaluation standard, 73 relates the liver and mediastinum FDG uptake to the residual tumor uptake at an early response time point. The specific Deauville cutoff that defines adequate or inadequate response depends on the time of assessment and intensity of the chemotherapy regimen. Therefore, the complete metabolic FDG-PET response for assessment of early response in trials using intensive treatment regimens is now defined as Deauville 1 to 3. 74, 75 For assessment of late response, Deauville scores of 3 or higher are considered FDG-PET positive, because this threshold may indicate residual tumor after chemotherapy. This strategy has successfully been applied in the German Hodgkin Study Group HD15 trial. 76 The definition of FDG-PET positivity by the older International Harmonization Project score, using the mediastinal blood pool and residual node size for reference, corresponds to a Deauville score of less than 3. Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AEPA, Adcetris (brentuximab vedotin), prednisone, etoposide, doxorubicin; mIFRT, modified involved-field radiotherapy; AHOPCA, Central American Association for Pediatric Hematology/Oncology; AR, adequate response after two cycles of initial OEPA chemotherapy (ie, PET negative [Ͻ DV4; ie, DV1-3]) and at least 50% volume reduction in bulk site; cht, chemotherapy; COG, Children's Oncology Group; COPDAC, cyclophosphamide, vincristine, prednisone, dacarbazine; CR, complete remission; DV, Deauville score for PET response assessment; 74 EORTC, European Organisation for Research and Treatment of Cancer; ERA, early response assessment after two cycles of initial OEPA chemotherapy; EuroNet-PHL, European Network for Pediatric Hodgkin Lymphoma; GHSG, German Hodgkin Study Group; IFRT, involved-field radiotherapy; INRT, involved-node radiotherapy; IR, inadequate response after two cycles of initial OEPA chemotherapy (ie, PET-positive Ն DV4 or Ͻ 50% volume reduction in bulk site; LRA, late response assessment after all chemotherapy; OEPA, vincristine, prednisone, etoposide, doxorubicin; PET, positron emission tomography; RER, rapid early responder; SER, slow early responder; TFRT, tailored-field radiotherapy.
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In 2014, Hasenclever et al 78 reported the quantitative PET evaluation methodology to quantify the Deauville score. This method provides a semiautomatic quantification for early FDG-PET response in HL and extends the ordinal Deauville scores to a continuous scale. Deauville categories correspond to certain qPET values. Thresholds between normal and abnormal response can be derived from the distribution of qPET values in a patient cohort. In the EuroNet-PHL-C1 trial, a certain qPET value after two cycles of OEPA chemotherapy helped differentiate an abnormal response with high sensitivity. Total tumor glycolytic or metabolic volume methods are also being investigated in pediatric HL.
79
FDG-PET-guided response adaptation is being increasingly used in pediatric HL. Figure 1 exemplifies how the concepts of response evaluation may be interpreted differently by different study groups, thereby affecting further therapy modifications. For the current EuroNet-PHL-C2 trial, the definitions for PET response will be changed to a higher threshold for PET positivity (Deauville 4) with the aim of increasing the percentage of patients in whom RT can be eliminated more than 50%. Accordingly, the patient shown in Figure  1 will not receive RT in the future.
Chemotherapy intensification will be one tool used to compensate for the elimination for RT. In the COG AHOD0031 trial, the chemotherapy response for the patient shown in Figure 1 would have been interpreted as non-CR (ie, Ͻ 80% reduction) by twodimensional anatomic response assessment, which would have also prompted IFRT after completing chemotherapy. The PET findings after two cycles of chemotherapy were visually assessed and documented, but in contrast to the EuroNet-PHL-C1 trial, they were not used to make further treatment decisions. The comparability of definitions for PET response and the varied use of CT criteria across cooperative trial groups remains an important source of controversy.
IMPROVING THE COMPARABILITY OF CLINICAL TRIAL RESULTS
To accurately compare the results of different trials, it is essential to confirm that equivalent criteria are used for staging, treatment allocation, and response assessment. Patients with HL are staged according to the Ann Arbor classification with or without the Cotswolds modification. 80 These criteria were defined in the 1960s and were based on clinical, surgical, and two-dimensional imaging modalities, whereas modern staging systems rely exclusively on anatomic cross-sectional imaging (CT-MRI [magnetic resonance imaging]), mostly in combination with functional scans (PET-CT or PET-MRI). This may result in a trend toward allocating patients to higher disease stages and consequently higher risk groups because of more refined imaging technologies and lead to overtreatment of some patients. However, risk stratification and treatment group allocation differ widely not only between adult and pediatric cooperative group trials but also among the major pediatric HL study groups, and sometimes even within the same group between generations of trials (Figure 2 ). Most study groups perform quality assurance through a central multidisciplinary reference board for oncology, radiology, nuclear medicine imaging, and RT within their trial series. Quality assurance offered through central reference and consultation centers can improve PFS rates by 10%. 81 The Pediatric Hodgkin Network, a Web-based image data exchange tool, has been established for quality assurance in the EuroNet-PHL trials for European and extra-European countries. 48,49 Leaders of major pediatric HL consortia from both sides of the Atlantic spearhead this ongoing effort. The harmonization process aims at higher comparability of treatment results among study groups and a more meaningful interpretation of prognostic factors, but it may require continuous updating. Harmonization is an ever-dynamic process, but it is indispensable for introducing new drugs and novel therapies in global trials.
EVALUATING TREATMENT FOR RARE OR UNIQUE HISTOPATHOLOGIES
The recognition of nodular lymphocyte-predominant HL (nLPHL) as a distinct entity by the WHO 84 has generated interest in testing different treatment approaches for cHL and nLPHL. Children with nLPHL have an OS of approximately 100%, and nLPHL is frequently found as a localized, early-stage disease. A meta-analysis of French, United Kingdom, and German trial series showed that surgery alone was a feasible option for localized disease, and yielded a long-term relapsefree survival of 67%.
85 COG AHOD03P1 prospectively evaluated 52 pediatric patients with stage I single-node disease treated with surgery alone. Twelve patients who had stage IA relapse went on to receive chemotherapy and had a 3-year OS of 100%; none of the patients required radiation. 41 For nLPHL patients with incomplete resection, anthracycline-free chemotherapy combinations may be more efficacious than RT-only approaches, such as those used in adult patients. 86 In a retrospective case series, Shankar et al 87 reported a 3-year freedom from treatment failure of 74% and OS of 100% for patients receiving cyclophosphamide, vinblastine, and prednisone chemotherapy. Only patients who did not at least achieve an unconfirmed CR (CRu; Յ 25% of the initial diagnostic nodal volume and Յ 2 mL) were treated with more intensive chemotherapy. In the prospective AHOD03P1 trial, 137 low-risk patients receiving three cycles of doxorubicin, vincristine, prednisone, and cyclophosphamide had a 4-year EFS of 88% and a 4-year OS of 100%. Only 11 patients did not achieve CR with this chemotherapy combination and required IFRT. 41 In a large retrospective report on 394 adult patients with nLPHL treated on cHL studies with a combination of chemotherapy and RT regimens, the relapse rate was not different between nLPHL and cHL patients. 88 In contrast, the entity gray zone lymphoma (GZL), as defined by the WHO, 89 is a disease with intriguing features but lacking standard treatment approaches. The features of GZL are intermediate between those of cHL and diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma or between nLPHL and T-cell-rich B-cell lymphoma or other variants. In a retrospective analysis, distinct histologic patterns of nLPHL in adults have been correlated to prognostic factors. 90 GZL, a rare entity, has been successfully treated either according to protocols for cHL or mature B-cell non-Hodgkin lymphoma, depending on whether the diagnosis was made at initial presentation or at the time of relapsed or progressive disease. A preliminary analysis of the German HL and N-HL registries 42 revealed that pediatric patients with GZL were treated with either standard HL regimens, such as OEPA-COPDAC with or without RT, or according to intensive regimens for primary mediastinal B-cell lymphoma, such as dose-adjusted etoposide, prednisone, cyclophosphamide, and doxorubicin plus rituximab. 91 For successfully treating such rare entities, establishing a proper histopathologic diagnosis, including confirmation by expert pathology review, is of 18 F]fluoro-deoxy-glucose (FDG) positron emission tomography (PET) computed tomography images and (B) nonfused PET images of corresponding coronal (upper panels) and transversal (lower panels) slices at initial diagnosis (left) and at response assessment after two cycles of intensive chemotherapy (right) for a 15-year-old patient with classical Hodgkin lymphoma. The blue arrows in the right panels indicate a small residual mass with slightly enhanced FDG uptake after two cycles of chemotherapy. The visual PET assessment was performed by five independent and specialized nuclear medicine physicians. Deauville (DV) criteria assessment varied from DV2 to DV4. Three experts assessed PET positivity as DV3, which was considered positive during the European Network for Pediatric Hodgkin Lymphoma Group trial C1 and was the basis for involved-field radiotherapy administration. In addition, the patient received a radiation boost to the residual mediastinal mass, which showed an anatomic volume reduction of less than 75%. The semiautomatic quantification of the residual PET signal resulted in a quantified PET value of 1.26, which also corresponded to DV3. utmost importance. Combined efforts for harmonization of diagnostic criteria across pediatric lymphoma study groups are required to facilitate global trials on these rare entities.
NEW AGENTS
In the last decade, efforts have focused on studying new drugs and compounds targeting epitopes or signaling pathways of the Hodgkin and Reed/Sternberg cells or the tumor microenvironment in relapsed or refractory patients. Targeting the B-cell receptor-dependent nuclear factor-B pathway with compounds such as bortezomib, a proteasome inhibitor that has favorable effects in vitro, has not proven effective in phase I and II trials.
92,93 A pediatric trial is currently evaluating panobinostat, a histone deacetylase inhibitor, in patients with relapsed HL, although this agent is likely more active when used in combination with other agents.
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CD30, a member of the tumor necrosis factor-␣ receptor family, which is expressed almost exclusively on HL cells, has been an attractive target for antibody therapy. Initial attempts of treatment with naked CD30 antibodies were unsuccessful but later improved when the antibody was coupled with radioactive compounds or cytotoxic drugs. Patients with relapsed and refractory HL administered brentuximab vedotin, an antibody-drug conjugate with the antitubulin agent monomethyl auristatin E, had favorable overall response rates. 95, 96 Long-term results have shown that brentuximab vedotin monotherapy as second-or third-line treatment has not proven curative in patients with multiple relapses; the results of trials with this compound in combination with conventional chemotherapy regimens are not yet available. According to the principle of a most effective first hit strategy, brentuximab vedotin has now been introduced into first-line treatment in adults 97 and children with HL. In an ongoing study of the St Jude-Stanford-Dana Farber consortium, brentuximab vedotin has replaced vincristine in the OEPA-COPDAC regimen for high-risk patients 98 with the aim of further reducing the number of high-risk patients who require RT. With the same aim, the COG is initiating a random assignment phase III trial to evaluate the efficacy of brentuximab vedotin in combination with AVE-PC chemotherapy.
99 This is part of the overall treatment strategy for pediatric HL to identify highly effective chemotherapy regimens that minimize late effects and reduce the need for RT for the majority of patients.
Nivolumab is another new agent currently under investigation that seems to be highly efficacious in relapsed and refractory patients with HL. This antibody may block the programmed death-1 pathway thought to be used by Hodgkin and Reed/Sternberg cells to evade immune detection. Early results are encouraging and suggest that nivolumab has an exceptionally safe profile, 100 thereby making it an attractive candidate for early evaluation in pediatric patients.
FUTURE DIRECTIONS AND CONCLUSIONS
Increasing our knowledge about the genetic risk factors associated with long-term sequelae can lead to the development of treatment strategies that consider the individual's genetic risk. Recently, Ma et al 101 showed that genetic polymorphisms of FGFR2 correlate Risk  IA  IB  IIA  IIB  IIIA  IIIB  IVA  IVB significantly with the risk of breast cancer after mediastinal irradiation. In addition, estrogens may induce oncogenic effects through FGFR2 signaling. 102 Furthermore, decreased basic expression of PRDM1, a tumor suppression gene, is significantly associated with radiation-induced secondary cancer after childhood HL. recently showed that variants of the human concentrative nucleoside transporter SLC28A1 as well as the cassette transporter genes ABCB4 or ABCC1 are significantly associated with an increased risk of anthracycline-induced cardiotoxicity.
Study Group
In the future, HL patients at high risk for anthracycline-induced cardiotoxicity may be treated with combined-modality strategies that limit anthracyclines, whereas patients at high risk for RT-induced second malignancies may benefit more from intensive chemotherapy regimens that spare RT. Multinational research programs that can correlate cumulative long-term risk factors with genetic polymorphisms are required to investigate the feasibility and benefits of genetically stratified therapy.
Between the end of the 1970s and the early 1990s, combinedmodality treatment approaches using chemotherapy with fairly low cumulative doses of anthracyclines and RT yielded high cure rates in children and adolescents with HL.
1,28,29,105,106 Since then, the indication for a stepwise reduction of RT has been evaluated by using a risk-stratified, response-adapted strategy according to anatomic and metabolic response criteria. Thus, regimens with quite intensive but toxic drug doses can compensate for RT and lead to excellent EFS rates, but they may result in lower long-term OS rates as demonstrated in a trial series on adults.
107 Future efforts in the treatment of both adults and children with HL should focus on developing personalized therapies, considering individual risk factors, and introducing new drugs with a safe profile that target specific HL pathways.
The progress and, consequently, the success in the treatment of pediatric HL have largely been achieved through collaborative efforts of national and multinational study groups. The ultimate goal for collaborative efforts has always been the reduction of treatment burden and the maintaining of high cure rates. In the future, novel therapies and targeted compounds should be studied thoroughly in ongoing collaborations to develop the most effective but even less toxic treatments. Because HL affects young people in the prime of their lives, it is important to efficiently control it. The effect of late toxicities of these treatments needs to be limited, as they have a significant effect on society as a whole.
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